In addition, unlike the gradually decreasing glucose-lowering effect of SGLT2 inhibitors in patients with chronic kidney disease, the effect of these agents on lowering blood pressure is similar in patients with different renal conditions, even those with a lower estimated glomerular filtration rate (eGFR) (33). This evidence concerns the gene SLC5A2 and chronic kidney disease.